Site-specific ROS inhibitors as potential therapeutic targets. The identification of redox signaling pathways that contribute to muscle contractile dysfunction may provide potential new targets for ...

As ROS levels surged, SFK activity spiked, helping melanoma cells withstand treatment. However, this adaptation was reversible—when treatment was removed, cells returned to their original state.

As ROS levels surged, SFK activity spiked ... Recognizing this Achilles heel, the team tested a combination approach: pairing BRAF inhibitors with the SFK inhibitor dasatinib.